This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: May 3

1. Less Than Hysteric Hemispherix

If Hemispherx Biopharma's (HEB - Get Report) board of directors is playing some kind of joke on its shareholders with its recent executive payouts then let us be the first to tell them it's not funny.

Extremely dumb, yes. Hysterically funny, no.

As TheStreet's biotech ax Adam Feuerstein brought to light Wednesday, Hemispherx CEO Bill Carter was awarded a 5% bonus totaling $1.1 million based on the net proceeds resulting from the sale of 30 million shares of company stock through an At-The-Market (ATM) financing arrangement last fall.

Hemispherx's board concluded the sale of company stock on the open market actually represented a sale of "company assets not in the ordinary course of its business." Under this definition, Carter was contractually eligible to receive 5% of the proceeds from a sale of 30 million shares of Hemispherx stock during the fourth quarter 2012 that netted $23 million for the company. Thomas Equels, Hemispherx's vice chairman and lawyer, also received the same $1.1 million "ATM bonus" under his employment contract.

Forget ATM as in At-The-Market, these clowns are using the company like an ATM as in Automatic Teller Machine! Carter and Equels are ostensibly supposed to be getting paid for selling drugs, not stocks. Furthermore, even boiler room brokers wouldn't charge 10% for a crappy penny stock like this.

"Hemispherx was selling those 30 million shares under the subterfuge of its ATM agreement which allows the company to disclose sales only when it files quarterly reports to the SEC. And of course, at that same time, Hemispherx shares were losing 80% of their value after the FDA and an independent advisory panel sharply criticized the company for the way it conducted clinical trials of the experimental chronic fatigue syndrome drug Ampligen," writes TheStreet's Feuerstein.

The panel voted not to recommend Ampligen for approval and the FDA rejected the drug, making it the second time Hemispherx has been turned away by U.S. regulators. Despite these miserable results, however, the company's sycophantic board deemed it kosher to pay millions to Carter and Equels.

Wait. We forgot one.

Obnoxiously greedy, yes. Definitely yes.

-- Written by Gregg Greenberg in New York City.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
CETV $2.30 0.00%
HEB $0.12 0.00%
HLF $44.64 0.00%
FB $102.01 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs